Is Concord Biotech (CONCORDBIO) overvalued or fairly valued?

MarketChacha shows Concord Biotech's valuation in context — a forward P/E of about 31.3, a price-to-book of about 6.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Concord Biotech's revenue?

Concord Biotech reported revenue of ₹1,055 Cr for FY2026, with net profit of ₹261 Cr, per official filings.

What is the share price of Concord Biotech (CONCORDBIO)?

Concord Biotech last traded at ₹1,283.60 (-3.9% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Concord Biotech

CONCORDBIO · NSE · Pharma · India

₹1,283.60-3.9%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 9:59 AM

Snapshot

TickerCONCORDBIO

ExchangeNSE

SectorPharma

IndustryBiotechnology

CountryIndia

Employees1,624

HeadquartersAhmedabad, India

Market cap₹13,429 Cr

P/B6.7

Volume91.64K

Websitewww.concordbiotech.com

Filings tracked0

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters72.5%
Institutions12.8%
Public & other14.7%

47 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

Margin has compressed by about 5.6 points over the period — profitability is trending down.

Net margin trend30.3% → 24.7%

Margin has compressed by about 5.6 points over the period — profitability is trending down.

Growth qualityrev 2% · PAT 3%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next fiscal year

Rev ₹1,482 Cr · EPS 41.07

Est. earnings growth +27.9%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹987.0052-wk range₹1,980.00

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹13,429 Cr

Day change

-3.9%

Fwd P/E

31.3

P/B

6.7

Div yield

0.57%

Beta

0.42

Revenue (FY2026)

₹1,055 Cr

Net margin

24.7%

Revenue CAGR (2y)

+1.8%

Profit CAGR (3y)

+2.8%

Net profit (FY2026)

₹261 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about CONCORDBIO

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹1,055 Cr	₹261 Cr	24.7%
FY2025	₹1,200 Cr	₹372 Cr	31.0%
FY2024	₹1,017 Cr	₹308 Cr	30.3%
FY2023	—	₹240 Cr	—

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹326 Cr	₹89 Cr	27.2%
2025Q4	₹278 Cr	₹64 Cr	23.2%
2025Q3	₹247 Cr	₹64 Cr	25.7%
2025Q2	₹204 Cr	₹44 Cr	21.6%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.